Larimar Therapeutics, Inc. (LRMR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.830.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LRMR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LRMR — earnings miss
Dated 2026-03-19
Results of Operations and Financial Condition. On March 19, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2025 and for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be fur…
Why it matters: Topline data will show how well nomlabofusp works. It will also show its safety.
Watch forTopline data shows clear clinical improvements. These improvements are better than the reference group.
Also watch forTopline data does not show clear improvements. It is not better than the reference population.
Why it matters: The launch timeline is crucial for future revenue. Approval is needed to proceed as planned.
Supportive ifManagement confirms a U.S. launch in the first half of 2027.
Worry ifIf the launch is late, it shows there are regulatory or development problems.
Why it matters: This submission is important for Larimar's progress. Delays could affect the launch.
Supportive ifFinal regulatory modules, including CMC, are due by the end of 2026-H2.
Worry ifSubmission is late compared to the planned timeline.
Why it matters: FDA feedback will show how likely nomlabofusp is to get faster approval.
Watch forFDA gives good feedback on the BLA submission data.
Also watch forFDA raises major concerns about the BLA submission data.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$298 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $747 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,874 loss on $10,000 · 48.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Updates on cash runway will indicate if Larimar can support its planned U.S. launch in 2027.
Supportive ifCash and investments remain sufficient to support the U.S. launch in the first half of 2027.
Worry ifCash runway updates show not enough funds for the planned launch.
Why it matters: This event is important for nomlabofusp. It shows progress and the company's commitment.
Supportive ifFirst patient dosing occurs in the global Phase 3 study in Q3 2026 as planned.
Worry ifDosing will not start in Q3 2026. This may mean delays in the clinical program.
Why it matters: Finishing the BLA submission is important for faster approval of nomlabofusp. It shows the company is on track.
Supportive ifThe final modules of the BLA submission are completed and submitted by the end of 2026.
Worry ifThe BLA submission is delayed past 2026. This suggests there are regulatory challenges.
Why it matters: Topline data will show how well nomlabofusp works. It will help with the BLA submission.
Supportive ifNew data shows skin FXN levels are stable. There are also clinical improvements.
Worry ifTopline data does not show major improvements. This raises concerns about how well the treatment works.